Literature DB >> 7004196

Chronic cryptococcal meningitis: a new experimental model in rabbits.

J R Perfect, S D Lang, D T Durack.   

Abstract

This paper describes the salient features of a new model for chronic cryptococcal meningitis in cortisone-treated rabbits. Normal rabbits soon recovered after intracisternal inoculation of Cryptococcus neoformans, but cortisone-treated animals developed chronic progressive meningitis that was fatal in 2-12 weeks. Incidence and severity of infection was related to cortisone dose, not to inoculum size. The number of mononuclear cells that migrated into the subarachnoid spaces and cerebrospinal fluid of infected rabbits was strikingly reduced by cortisone treatment. Rabbits with cryptococcal meningitis were febrile; their high body temperature did not confer resistance to this infection. Cortisone-treated rabbits provide a new and expedient laboratory model for cryptococcal disease. Potential applications include study of the pathogenesis of cryptococcosis, investigation of the immunobiology of the CNS in chronic meningitis, and in vivo evaluation of newer anticryptococcal treatment regimens.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7004196      PMCID: PMC1903580     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  21 in total

1.  Cryptococcosis in animals.

Authors:  C N BARRON
Journal:  J Am Vet Med Assoc       Date:  1955-08       Impact factor: 1.936

2.  Effects of stimulation and suppression of cell-mediated immunity on experimental cryptococcosis.

Authors:  R D Diamond
Journal:  Infect Immun       Date:  1977-07       Impact factor: 3.441

3.  Diagnosis and treatment of cryptococcal disease.

Authors:  A Spickard
Journal:  South Med J       Date:  1973-01       Impact factor: 0.954

4.  Disseminated cryptococcosis in man: decreased lymphocyte transformation in response to Cryptococcus neoformans.

Authors:  R D Diamond; J E Bennett
Journal:  J Infect Dis       Date:  1973-06       Impact factor: 5.226

5.  Cell-mediated immunity in Cryptococcosis.

Authors:  J R Graybill; R H Alford
Journal:  Cell Immunol       Date:  1974-10       Impact factor: 4.868

6.  The wide spectrum of cryptococcal infections.

Authors:  J L Lewis; S Rabinovich
Journal:  Am J Med       Date:  1972-09       Impact factor: 4.965

7.  Experience with a new skin test antigen prepared from Cryptococcus neoformans.

Authors:  A J Atkinson; J E Bennett
Journal:  Am Rev Respir Dis       Date:  1968-04

8.  Cryptococcal meningitis associated with steroid therapy.

Authors:  T S Wilson; W A Fleming; F L Robinson; B Nicholl
Journal:  J Clin Pathol       Date:  1970-11       Impact factor: 3.411

9.  Invasive aspergillosis: antiserum for circulating antigen produced after immunization with serum from infected rabbits.

Authors:  P F Lehmann; E Reiss
Journal:  Infect Immun       Date:  1978-05       Impact factor: 3.441

10.  Effect of a tetracycline antibiotic on the experimental pathogenicity of Cryptococcus neoformans.

Authors:  V Strippoli; N Simonetti; A Cassone
Journal:  Chemotherapy       Date:  1978       Impact factor: 2.544

View more
  156 in total

1.  Antibody response to Cryptococcus neoformans proteins in rodents and humans.

Authors:  L C Chen; D L Goldman; T L Doering; L a Pirofski; A Casadevall
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Major histocompatibility complex controls the trajectory but not host-specific adaptation during virulence evolution of the pathogenic fungus Cryptococcus neoformans.

Authors:  Erin E McClelland; Frederick R Adler; Donald L Granger; Wayne K Potts
Journal:  Proc Biol Sci       Date:  2004-08-07       Impact factor: 5.349

3.  Cryptococcus neoformans mitochondrial genomes from serotype A and D strains do not influence virulence.

Authors:  Dena L Toffaletti; Kirsten Nielsen; Fred Dietrich; Joseph Heitman; John R Perfect
Journal:  Curr Genet       Date:  2004-08-07       Impact factor: 3.886

4.  High-resolution melting analysis for identification of the Cryptococcus neoformans-Cryptococcus gattii complex.

Authors:  Sara Gago; Óscar Zaragoza; Isabel Cuesta; Juan L Rodríguez-Tudela; Manuel Cuenca-Estrella; María J Buitrago
Journal:  J Clin Microbiol       Date:  2011-08-10       Impact factor: 5.948

5.  Urease as a virulence factor in experimental cryptococcosis.

Authors:  G M Cox; J Mukherjee; G T Cole; A Casadevall; J R Perfect
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

6.  Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide.

Authors:  D L Goldman; S C Lee; A J Mednick; L Montella; A Casadevall
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

7.  Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule.

Authors:  Michelle E Maxson; Ekaterina Dadachova; Arturo Casadevall; Oscar Zaragoza
Journal:  Eukaryot Cell       Date:  2006-11-17

8.  The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug.

Authors:  Ana Cecilia Mesa-Arango; Nuria Trevijano-Contador; Elvira Román; Ruth Sánchez-Fresneda; Celia Casas; Enrique Herrero; Juan Carlos Argüelles; Jesús Pla; Manuel Cuenca-Estrella; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

9.  Multilocus sequence typing reveals three genetic subpopulations of Cryptococcus neoformans var. grubii (serotype A), including a unique population in Botswana.

Authors:  Anastasia P Litvintseva; Rameshwari Thakur; Rytas Vilgalys; Thomas G Mitchell
Journal:  Genetics       Date:  2005-12-01       Impact factor: 4.562

10.  Effects of cyclosporine in experimental cryptococcal meningitis.

Authors:  J R Perfect; D T Durack
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.